Prevalence and prognostic impact of ascites, hepatorenal syndrome and hepatorenal syndrome and hyponatremia in cirrhotic patients.
DOI:
https://doi.org/10.35954/SM2018.37.1.9Keywords:
Ascites; Liver Cirrhosis;, Ascites; Liver Cirrhosis; Hyponatremia; Hepatorenal SyndromeAbstract
Cirrhosis represents the final common stage to which different chronic liver diseases converge. As the disease progresses with the development of portal hypertension, complications such as ascites, hepatorenal syndrome and hyponatremia appear. The development of any of these complications marks a turning point in the evolution of the disease with remarkable prognostic impact. The aim of the present work is to describe the characteristics of a cohort of advanced cirrhotic patients mainly regarding the development of complications of advanced portal hypertension (hyponatremia, ascites and hepatorenal syndrome), their prognostic impact, and survival to death or liver transplantation. Forty patients were analyzed and followed up for a period of 2 years. Regarding the complications that were the focus of the analysis, the most frequent was ascites (40%) followed by hyponatremia and hepatorenal syndrome (HRS) with 7.5% and 5% respectively. Although a difference was found between the presence and absence of these complications with an increase in the need for liver transplantation or death, it was not statistically significant. This result is possibly conditioned by the low number of patients and the follow-up time of the study. We should have studies that include a larger number of patients in order to be able to draw valid conclusions. Nevertheless, the presence of the complications analyzed should alert the physician to the seriousness of the situation and the need for early referral of these patients for evaluation at a liver transplant center.
Downloads
Metrics
References
(1) Ginés P, Arroyo V. Cirrosis hepática. En: Farreras P, Rozman C. Medicina Interna, 17a. ed. Barcelona, Elsevier, 2012; 314-19.
(2) Sola E, Ginés P. Renal and circulatory dysfunction in cirrhosis: Current management and future perspec-tives. J Hepatol 2010; 53(6):1135-1145.
(3) Arroyo V, Ginés P, Gerbes A, Dudley F, Gentilini P, Laffi G, et al. Definition and Diagnostic Criteria of Refractory Ascites and Hepatorenal Syndrome in Cirrhosis. Hepatology 1996; 23(1):164-76.
(4) Arroyo V, Rodés J, Gutiérrez-Lizárraga M, Revert L. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976; 21(3):249-56.
(5) Ginés P, Guevara M. Hyponatremia in Cirrhosis: Pathogenesis, Clinical Significance, and Manage-ment. Hepatology 2008; 48:1002-1010.
(6) Ginés P, Berl T, Bernardi M, Bichet D, Hamon G, Jimenez W, et al. Hyponatremia in Cirrhosis: From Pathogenesis to Treatment. Hepatology 1998; 28(3):851-64.
(7)Porcel A, Diaz F, Rendón P, Macías M, Martín-Herrera L, Girón-Gonzalez J. Dilitional Hy-ponatremia in Patients with Cirrhosis and Ascities. Arch Intern Med 2002; 162(3):323-8.
(8) Borroni G, Maggi A, Sangiovanni A, Cazzaniga M, Salerno F. Clinical relevance of hyponatre-mia for the hospital outcome of cirrhotic patients. Dig Liver Dis 2000; 32(7):605-10.
(9) Angeli P, Wong F, Watson H, Ginés P, and the CAPPS Investigators. Hyponatremia in Cirrhosis: Results of a patient population survey. Hepatology 2006; 44:1535-1542.
(10) Ruf A, Kremers W, Chavez L, Descalzi V, Podesta L, Villamil F. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11(3):336-43.
(11) Biggins S, Rodriguez H, Bacchetti P, Bass N, Roberts J, Terrault N. Serum sodium predicts mortali-ty in patients listed for liver transplantation. Hepatology 2005; 41(1):32-9.
(12) Heuman D, Abou-assi S, Habib A, Williams L, Stravitz R, Sanyal A. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40(4):802-10.
(13) Dawwas M, Lewsey J, Neuberger J, Gimson A. The impact of serum sodium concentration on mor-tality after liver transplantation: a cohort multicenter study. Liver Transpl 2007; 13(8):1115-24.
(14) Londoño MC, Guevara M, Rimola A, Navasa M, Taurà P, Mas A et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrho-sis undergoing liver transplantation. Gastroenterology 2006; 130(4):1135-43.
(15) Guevara M, Baccaro ME, Torre A, Gómez-An-són B, Ríos J, Torres F et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 2009; 104(6):1382-9.
(16) Runyon B, AASLD Practice Guidelines Commit-tee. Management of Adult Patients with Ascites Due to Cirrhosis: An Update. Hepatology 2009; 49(6):2087-107.
(17) Lucena M, Andrade R, Tognoni G, Hidalgo R, De La Cuesta F; Spanish Collaborative Study Group On Therapeutic Management In Liver Disease. Mul-ticenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrho-sis. Eur J Clin Pharmacol 2002; 58(6):435-40.
(18) D’Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986 May;31(5):468-75.
(19) Fortune B, Cardenas A. Ascites, refractory asci-tes and hyponatremia in cirrhosis.Gastroenterology Report 2017; 5(2):104-112.
(20) Ginés A, Escorsell A, Ginés P, Saló J, Jiménez W, Inglada L. Incidence, predictive factors, and prog-nosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105(1):229-36.
(21) Salerno F, Gerbes A, Ginés P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56(9):1310-8.
(22) Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62:968-974.
(23) Orlandi F, Christensen E. A consensus confer-ence on prognostic studies in hepatology. J Hepatol 1999; 30(1):171-2.
(24) Child C, Turcotte J. Surgery and portal hyperten-sion. In: The Liver and Portal Hypertension. Child C. (Ed) Saunders, Philadelphia 1964; pág. 50.
(25) Pugh R, Murray-Lyon I, Dawson J, Pietroni M, Williams R. Transection of the oesophagus for bleed-ing oesophageal varices. Br J Surg 1973; 60:646-9.
(26) D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrho-sis: a systematic review of 118 studies. J Hepatol 2006; 44(1):217-31.
(27) Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen P, Juhl E et al. Prognostic value of Child-Turcotte criteria in medically treated cirrho-sis. Hepatology 1984; 4(3):430-5.
(28) Christensen E. Prognostic models in chronic liv-er disease: validity, usefulness and future role. J Hepatol 1997; 26(6):1414-24.
(29) Malinchoc M, Kamath P, Gordon F, Peine C, Rank J, ter Borg P. A model to predict poor survival in patients undergoing transjugular intrahepatic por-tosystemic shunts. Hepatology 2000; 31(4):864-71.
(30) Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33(2):464-70.
(31) Wiesner R, McDiarmid S, Kamath P, Edwards E, Malinchoc M, Kremers W, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7(7):567-80.
(32) Said A, Williams J, Holden J, Remington P, Gang-non R, Musat A, et al. Model for end stage liver dis-ease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40(6):897-903.
(33) Freeman R, Edwards E. Liver transplant waiting time does not correlate with waiting list mortality: im-plications for liver allocation policy. Liver Transpl 2000; 6(5):543-52.
(34) Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver dis-ease (MELD) and allocation of donor livers. Gastroenterology 2003; 124(1):91-6.
(35) Freeman R, Wiesner R, Harper A, McDiarmid S, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplanta-tion policy. Liver Transpl 2002; 8(9):851-8.
(36) Ravaioli M, Grazi G, Ballardini G, Cavrini G, Er-colani G, Cescon M, et al. Liver transplantation with the Meld system: a prospective study from a single European center. Am J Transplant 2006; 6(7):1572-7.
(37) Kamath P, Kim W. Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007; 45(3):797-805.
(38) Sharma P, Schaubel D, Sima C, Merion R, Lok A. Re-weighting the model for end-stage liver dis-ease score components. Gastroenterology 2008; 135(5):1575-81.
(39) Leise M, Kim W, Kremers W, Larson J, Benson J, Therneau T. A revised model for end-stage liver disease optimizes prediction of mortality among pa-tients awaiting liver transplantation. Gastroenterology 2011; 140(7):1952-60.
(40) Saunders J, Walters J, Davies A, Paton A. A 20-year prospective study of cirrhosis. Br Med J (Clin Res Ed). 1981; 282(6260):263-6.
(41) De Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43(1):167-76.
(42) Centers for Disease Control. Deaths and hospital-izations from chronicliver disease and cirrhosis-United States, 1980-1989. JAMA 1993; 269:569-572.
(43) Lieber CS. Medical disorders of alcoholism. N Engl J Med 1995; 333:1058-1065.
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
